Risk factor
Meaningful price volatility
Profitability factor
Very strong margins and returns
In Guru Portfolios
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
Electromed, Inc. is engaged in the creation, production, and sale of respiratory therapy devices. Their focus is on delivering airway clearance through High Frequency Chest Wall Oscillation (HFCWO) technology, aiding pulmonary care for individuals of all ages across the United States and globally. The company's key offering is the SmartVest airway clearance system. This includes the SmartVest SQL System, an innovative solution comprising an inflatable therapy garment, a customizable air pulse generator, and a distinctive single-hose design for air delivery. They also provide SmartVest Connect, a wireless platform enabling personalized HFCWO therapy management for patients with diminished lung function. For acute care settings, Electromed supplies single-use SmartVest and SmartVest Wrap products to healthcare providers. Electromed's primary market is home healthcare, catering to patients diagnosed with conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disease. The company distributes its products via medical professionals, healthcare facilities, and directly to consumers. Established in 1992, Electromed, Inc. is based in New Prague, Minnesota.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA, overpriced
Target Price
The average target price of ELMD is 38 and suggests 3.5% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s